Quantum-Si Incorporated Announces Pricing of $50 Million Registered Direct Offering of Common Stock
Quantum-Si (QSI) has announced a registered direct offering of 15,625,000 shares of common stock priced at $3.20 per share, aiming to raise approximately $50 million in gross proceeds. The offering is expected to close around January 6, 2025, subject to customary closing conditions.
The company plans to use the net proceeds for working capital and general corporate purposes. A.G.P./Alliance Global Partners is serving as the sole placement agent for this offering, which is being conducted under an effective shelf registration statement on Form S-3 that was declared effective by the SEC on August 22, 2023.
Quantum-Si (QSI) ha annunciato un offerta diretta registrata di 15.625.000 azioni ordinarie al prezzo di $3,20 per azione, con l'obiettivo di raccogliere circa $50 milioni in proventi lordi. Si prevede che l'offerta si chiuda intorno al 6 gennaio 2025, soggetta alle condizioni di chiusura abituali.
L'azienda prevede di utilizzare i proventi netti per il capitale circolante e scopi aziendali generali. A.G.P./Alliance Global Partners funge da unico agente per questa offerta, che viene condotta sotto una dichiarazione di registrazione efficace su modulo S-3 dichiarata efficace dalla SEC il 22 agosto 2023.
Quantum-Si (QSI) ha anunciado una oferta directa registrada de 15,625,000 acciones ordinarias a un precio de $3.20 por acción, con el objetivo de recaudar aproximadamente $50 millones en ingresos brutos. Se espera que la oferta cierre alrededor del 6 de enero de 2025, sujeta a condiciones de cierre habituales.
La compañía planea utilizar los ingresos netos para capital de trabajo y propósitos corporativos generales. A.G.P./Alliance Global Partners está actuando como el único agente colocador para esta oferta, que se está llevando a cabo bajo una declaración de registro efectiva en el formulario S-3 que fue declarada efectiva por la SEC el 22 de agosto de 2023.
Quantum-Si (QSI)는 등록 직접 공모를 통해 15,625,000주의 보통주를 주당 $3.20의 가격으로 판매한다고 발표했습니다. 이는 약 $50 백만의 총 수익을 목표로 하고 있습니다. 이 공모는 2025년 1월 6일경에 마감될 것으로 예상되며, 일반적인 마감 조건에 따라 진행됩니다.
회사는 순수익을 운영 자금 및 일반 기업 목적으로 사용할 계획입니다. A.G.P./Alliance Global Partners는 이 공모의 단독 배치 에이전트로 활동하고 있으며, 이는 SEC에 의해 2023년 8월 22일에 유효한 S-3 양식으로 등록된 효과적인 선반 등록 성명 하에 이루어집니다.
Quantum-Si (QSI) a annoncé une offre directe enregistrée de 15 625 000 actions ordinaires au prix de 3,20 $ par action, avec pour objectif de lever environ 50 millions $ de produits bruts. On s'attend à ce que l'offre se clôture aux alentours du 6 janvier 2025, sous réserve des conditions de clôture habituelles.
L'entreprise prévoit d'utiliser les produits nets pour le fonds de roulement et les besoins généraux de l'entreprise. A.G.P./Alliance Global Partners agit en tant qu'agent de placement unique pour cette offre, qui est effectuée sous une déclaration d'enregistrement effective sur le formulaire S-3, déclarée effective par la SEC le 22 août 2023.
Quantum-Si (QSI) hat ein registriertes Direct Offering von 15.625.000 Stammaktien zum Preis von 3,20 $ pro Aktie angekündigt, mit dem Ziel, etwa 50 Millionen $ brutto zu erzielen. Es wird erwartet, dass das Angebot rund um den 6. Januar 2025 abgeschlossen wird, vorbehaltlich üblicher Abschlussbedingungen.
Das Unternehmen plant, die Nettoerlöse für Betriebskapital und allgemeine Unternehmenszwecke zu verwenden. A.G.P./Alliance Global Partners fungiert als alleiniger Platzierungsagent für dieses Angebot, das im Rahmen einer wirksamen Shelf-Registrationserklärung in Form S-3 durchgeführt wird, die am 22. August 2023 von der SEC für wirksam erklärt wurde.
- Secured $50 million in additional funding through stock offering
- Strengthens working capital position
- 15.6M new shares will cause significant shareholder dilution
- Offering price of $3.20 per share may pressure current stock price
Insights
The
The timing of this capital raise appears strategic, as it provides QSI with additional runway to fund their protein sequencing technology commercialization efforts. Working capital strengthening is important given the capital-intensive nature of the biotech sector and current market conditions. The company's ability to secure institutional investors in this environment demonstrates some confidence in their technology platform, though the discount pricing suggests cautious investor sentiment.
The use of a registered direct offering, while more streamlined than a traditional public offering, typically indicates a desire for a faster closing process with targeted institutional investors. A.G.P.'s involvement as placement agent adds credibility to the transaction, though the offering's structure suggests broader market appetite.
This capital injection comes at a critical juncture for Quantum-Si's protein sequencing platform development. The proteomics market is highly competitive and maintaining adequate funding is essential for continuing R&D efforts and commercial rollout strategies. The
The institutional investor participation suggests some validation of QSI's technology approach, though the pricing terms indicate ongoing market skepticism about near-term commercialization prospects. The protein sequencing space is witnessing rapid technological evolution and this funding will be important for QSI to maintain its competitive position against both established players and emerging startups.
For retail investors, it's worth noting that while dilution is significant, the enhanced balance sheet strength reduces near-term financing risk. The key focus should be on monitoring the company's progress in translating this capital into tangible commercial advancement of their protein sequencing platform.
The Company intends to use the net proceeds from the offering for working capital and general corporate purposes.
A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.
This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-273934) which was declared effective by the Securities and Exchange Commission (the “SEC”) on August 22, 2023. The offering is made only by means of a prospectus which is part of the effective registration statement. A final prospectus supplement and the accompanying prospectus relating to the registered direct offering will be filed with the SEC and will be available on the SEC's website located at http://www.sec.gov. Additionally, when available, electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor,
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum® instrument enables Next-Gen Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.
Forward Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance and development and commercialization of products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company’s Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company’s ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product development and commercialization activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized Platinum® protein sequencing instrument and kits and the Company’s other products once commercialized; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties described under "Risk Factors" in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company’s other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250103744010/en/
Investor Contact
Jeff Keyes
Chief Financial Officer
ir@quantum-si.com
Media Contact
Katherine Atkinson
SVP, Commercial Marketing
media@quantum-si.com
Source: Quantum-Si Incorporated
FAQ
How much money is Quantum-Si (QSI) raising in its January 2025 stock offering?
What is the price per share for QSI's January 2025 stock offering?
When will QSI's $50 million stock offering close?
How will Quantum-Si use the proceeds from its $50M stock offering?
Who is the placement agent for QSI's January 2025 stock offering?
